Contact
searchSearch
HMP Global
Login

Expert Insights

Diwakar Davar, MBBS
Videos
PRAME-Directed T-Cell Receptor Therapy Demonstrates Durable Responses in Advanced Melanoma
08/18/2026
Diwakar Davar, MBBS
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses...
08/18/2026
Oncology
Shubham Pant, MD
Videos
Beyond Chemotherapy: Targeting RAS in Metastatic Pancreatic Cancer
08/17/2026
Shubham Pant, MD
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how...
08/17/2026
Oncology
Craig L. Slingluff, Jr., MD
Videos
Long-Term Follow-Up Demonstrates Improved Outcomes With Two-Site Peptide Vaccination in Melanoma
08/12/2026
Craig Slingluff, MD
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses...
08/12/2026
Oncology
Sikander Ailawadhi, MD
Videos
FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
Barbara Burtness, MD
Videos
Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer
08/06/2026
Barbara Burtness, MD, FASCO
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses...
08/06/2026
Oncology
Podcasts
Real-World Decision Points in Biomarker-Driven NSCLC Management
08/05/2026
Jamie Chaft, MD
Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results,...
Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results,...
Dr Jamie Chaft discusses how...
08/05/2026
Oncology
Videos
Testing Across the Patient Journey: Longitudinal Biomarker Strategy in NSCLC
08/05/2026
Jamie Chaft, MD
In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...
In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...
In this video, Jamie Chaft, MD,...
08/05/2026
Oncology
Podcasts
Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling
08/05/2026
Jamie Chaft, MD
Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well...
Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well...
Dr Jamie Chaft reviews the...
08/05/2026
Oncology
Videos
Not All MET Biomarkers Are the Same: Matching the Right Test to the Right Target
08/05/2026
Jamie Chaft, MD
In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....
In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....
In this video, Jamie Chaft, MD,...
08/05/2026
Oncology
Podcasts
Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC
08/05/2026
Jamie Chaft, MD
Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion...
Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion...
Dr Jamie Chaft reviews the...
08/05/2026
Oncology

Recent News

News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
An ESMO Clinical Practice...
08/19/2026
Oncology
News
Datopotamab Deruxtecan Delays Quality-of-Life Deterioration Compared With Chemotherapy in HR-Positive, HER2-Negative Breast Cancer
08/19/2026
Emily Estrada
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and...
08/19/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Intismeran Plus Pembrolizumab Outperforms Pembrolizumab Alone in Resected Stage IIB-IV Melanoma
08/19/2026
Stephanie Holland
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3...
08/19/2026
Oncology
News
Rucaparib Plus Nivolumab Shows Biomarker-Linked Activity in Advanced Biliary Tract Cancer
08/19/2026
Emily Estrada
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02...
08/19/2026
Oncology
News
Tisagenlecleucel Shows Durable Five-Year Remissions in Pediatric and Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
08/19/2026
Emily Estrada
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase...
08/19/2026
Oncology
News
Third-Generation Anti-CD30 CAR T-Cell Therapy Shows Durable Responses in Relapsed or Refractory CD30-Positive Lymphoma
08/18/2026
Emily Estrada
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial...
08/18/2026
Oncology
News
Spartalizumab Triplet Extends Overall Survival in BRAF V600–Mutant Advanced Melanoma
08/18/2026
Stephanie Holland
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3...
08/18/2026
Oncology
News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Outperforms Cisplatin Plus Gemcitabine in Muscle-Invasive Bladder Cancer
08/12/2026
Stephanie Holland
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3...
08/12/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use